# my omorrows

#### Tailored access and real world performance

A sustainable model of medicine development


5 June 2018 Zeist



#### Problem (Paradise Lost)


#### Despite good intentions, drug development fails

- Rising drug costs prompt fears of sustainability and financial toxicity in healthcare
- Drug development and access models have not evolved with the advances in science and technology
- Numerous drugs enter the market without evidence of benefit on survival or quality of life
- Patients and doctors facing unmet needs want **faster access** to best drugs
- Clinical studies are exclusive, 95% of patients are not eligible
- Most reimbursement systems obstruct early access and (unintentionally)
  maintain the status quo




## τ

#### Eroom's law



Source: Nature (2016) Can you teach old drugs new tricks?

#### Return on investment in pharma R&D



Source: EvaluatePharma, IRR analysis (2017)



#### Signs of new development & access models

Forbes / Pharma & Healthcare / #Medicine MAY 11, 2018 @ 12:25 AM 3,576 ♥

# Will Real World Performance Replace RCTs As Healthcare's Most Important Standard?




Opinions expressed by Forbes Contributors are their own.







#### A new drug development model





#### Leveraging technology and existing regulations gives...

...physicians & patients with no treatment options access to drugs in development

...payors 'real' data and 'fair' drug prices

...way to accelerated **innovation** and increased **competition** in the pharma industry

...biotech entrepreneurs a pathway to build their company and keep control



"This is a system that is going to implode...The only way is to get rid of the inefficiency in the system. That's where I see digital technology starting to have a significant impact."

Departing Novartis Chief Executive Joe Jimenez in Forbes, 7 September 2017

### -- END --

myTomorrows.com